Research programme: CXCR3 antagonists - Millennium/Sanofi-Aventis
Alternative Names: 5H7 monoclonal antibodyLatest Information Update: 29 Jun 2006
Price :
$50 *
At a glance
- Originator Millennium Pharmaceuticals; sanofi-aventis
- Class Monoclonal antibodies
- Mechanism of Action CXCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 20 May 2004 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 20 May 2004 No development reported - Preclinical for Psoriasis in USA (unspecified route)